Sanara MedTech: From Cash Burner To Profitable Growth

Sanara MedTech delivered a strong Q1 2026, with 19% revenue growth, 93%+ gross margins, and its first GAAP profit in years. SMTI's strategic discontinuation of the THP segment has materially improved profitability, allowing management to focus on the high-return Surgical business. Operating margins now exceed 10%, and guidance for 2026 revenue is $116M–$121M, supporting a Buy rating despite the recent 30% stock rally.